Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM.

baricitinib fatigue pain productivity recovery of function rheumatoid arthritis

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
05 Sep 2019
Historique:
received: 28 08 2019
accepted: 03 09 2019
entrez: 8 9 2019
pubmed: 8 9 2019
medline: 8 9 2019
Statut: epublish

Résumé

Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks' treatment with baricitinib, adalimumab or placebo in the 52-week RA-BEAM phase III study. Adults with active RA and inadequate response to methotrexate received baricitinib 4 mg once daily, adalimumab 40 mg every two weeks or placebo, with background methotrexate. Patients (

Identifiants

pubmed: 31492040
pii: jcm8091394
doi: 10.3390/jcm8091394
pmc: PMC6780319
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Eli Lilly and Company
ID : N/A

Références

Ann Rheum Dis. 2017 Jan;76(1):88-95
pubmed: 27689735
Int J Rheum Dis. 2012 Aug;15(4):380-9
pubmed: 22898218
J Immunol. 2010 May 1;184(9):5298-307
pubmed: 20363976
J Rheumatol. 2005 May;32(5):811-9
pubmed: 15868614
J Rheumatol. 1982 Sep-Oct;9(5):789-93
pubmed: 7175852
J Rheumatol. 2014 Jul;41(7):1263-9
pubmed: 24833758
N Engl J Med. 2017 Feb 16;376(7):652-662
pubmed: 28199814
Arthritis Res Ther. 2012 Sep 20;14(5):R199
pubmed: 22995428
Arthritis Care Res (Hoboken). 2012 Feb;64(2):206-14
pubmed: 22052672
J Int Med Res. 2010 Jul-Aug;38(4):1213-24
pubmed: 20925993
Scand J Rheumatol. 2012 Oct;41(5):366-74
pubmed: 22803639
J Neurochem. 2008 Oct;107(1):50-60
pubmed: 18636982
Rheumatol Int. 2016 May;36(5):685-95
pubmed: 26746843
J Clin Med. 2019 Jun 12;8(6):null
pubmed: 31212775
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
Curr Rheumatol Rep. 2016 Jun;18(6):30
pubmed: 27097817
Arthritis Rheumatol. 2017 Mar;69(3):506-517
pubmed: 27723271
Ann Rheum Dis. 2009 Nov;68(11):1680-5
pubmed: 19054825
Arthritis Rheumatol. 2016 Jan;68(1):1-26
pubmed: 26545940
Rheumatol Int. 2018 Jun;38(6):935-947
pubmed: 29564549
Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii111-5
pubmed: 23532440
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
Nat Rev Rheumatol. 2014 Oct;10(10):581-92
pubmed: 24861185
Joint Bone Spine. 2008 Jul;75(4):408-15
pubmed: 18455949
Mod Rheumatol. 2018 Sep;28(5):789-799
pubmed: 29251034
Mod Rheumatol. 2018 Nov;28(6):950-959
pubmed: 29278006
Ann Rheum Dis. 2016 Nov;75(11):2054-2056
pubmed: 27558985
N Engl J Med. 2016 Mar 31;374(13):1243-52
pubmed: 27028914
Ann Rheum Dis. 2017 May;76(5):855-861
pubmed: 27903508
Disabil Rehabil. 2015;37(8):686-91
pubmed: 25036855

Auteurs

Bruno Fautrel (B)

Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Universités, GRC 08, 75646 Paris, France. Bruno.fautrel@aphp.fr.
Department of Rheumatology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, 83 bd de l'hôpital, 75013 Paris, France. Bruno.fautrel@aphp.fr.

Bruce Kirkham (B)

Department of Rheumatology, Guys and St Thomas' NHS Trust, Great Maze Pond, London SE1 9RT, UK. bruce.kirkham@gstt.nhs.uk.

Janet E Pope (JE)

Department of Medicine, Division of Rheumatology, University of Western Ontario, 1151 Richmond St, London, ON N6A 3K7, Canada. Janet.Pope@sjhc.london.on.ca.

Tsutomu Takeuchi (T)

Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. tsutake@z5.keio.jp.

Carol Gaich (C)

Eli Lilly and Company, Indianapolis, IN 46285, USA. GAICH_CAROL_LYNN@LILLY.COM.

Amanda Quebe (A)

Eli Lilly and Company, Indianapolis, IN 46285, USA. amanda.quebe@lilly.com.

Baojin Zhu (B)

Eli Lilly and Company, Indianapolis, IN 46285, USA. zhu_baojin@lilly.com.

Inmaculada de la Torre (I)

Eli Lilly and Company, Indianapolis, IN 46285, USA. ide_la_torre@lilly.com.

Francesco De Leonardis (F)

Eli Lilly and Company, Indianapolis, IN 46285, USA. deleonardis.francesco@lilly.com.

Peter C Taylor (PC)

Botnar Research Centre, NDORMS, University of Oxford, Old Road, Oxford OX3 7LD, UK. peter.taylor@kennedy.ox.ac.uk.

Classifications MeSH